Immuneering (IMRX) Total Current Liabilities (2020 - 2026)

Immuneering's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 2.62% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (down 2.62% YoY), while the FY2025 annual figure was $10.1 million, up 34.25% from the prior year.
• Total Current Liabilities was $5.0 million for Q1 2026 at Immuneering, down from $10.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.1 million in Q4 2025 to a low of $3.7 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $6.5 million across 5 years, with a median of $6.8 million in 2024.
• Biggest YoY gain for Total Current Liabilities was 50.41% in 2023; the steepest drop was 22.51% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $8.1 million in 2022, then declined by 2.59% to $7.8 million in 2023, then decreased by 4.36% to $7.5 million in 2024, then surged by 34.25% to $10.1 million in 2025, then sank by 50.62% to $5.0 million in 2026.
• The last three Total Current Liabilities figures came in at $5.0 million (Q1 2026), $10.1 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.